カテゴリ： QYResearch, 世界, 消費財/食品

筋緊張性ジストロフィー治療薬の世界市場2023年：ナトリウムチャネル遮断薬、三環系抗うつ薬、その他

■ 英語タイトル：Global Myotonic Dystrophy Drug Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8824）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8824
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：85
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[筋緊張性ジストロフィー治療薬の世界市場2023年：ナトリウムチャネル遮断薬、三環系抗うつ薬、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料は筋緊張性ジストロフィー治療薬のグローバル市場について調査・分析し、世界の筋緊張性ジストロフィー治療薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（ナトリウムチャネル遮断薬、三環系抗うつ薬、その他）、用途別セグメント分析（病院薬局、小売店薬局、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Lupin、Teva、ANI Pharmaceuticals、Mylan、Novartis、Sun Pharma、Mallinckrodtなどが含まれています。筋緊張性ジストロフィー治療薬のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、筋緊張性ジストロフィー治療薬市場規模を算出する際に考慮しました。

・筋緊張性ジストロフィー治療薬市場の概要
- 製品の定義
- 筋緊張性ジストロフィー治療薬の種類別セグメント
- 世界の筋緊張性ジストロフィー治療薬市場規模：タイプ別分析（ナトリウムチャネル遮断薬、三環系抗うつ薬、その他）
- 筋緊張性ジストロフィー治療薬の用途別セグメント
- 世界の筋緊張性ジストロフィー治療薬市場規模：用途別分析（病院薬局、小売店薬局、その他）
- 世界の筋緊張性ジストロフィー治療薬市場規模予測（2018年-2029年）
- 筋緊張性ジストロフィー治療薬の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 筋緊張性ジストロフィー治療薬市場の競争状況およびトレンド

・筋緊張性ジストロフィー治療薬の地域別市場規模
- 北米の筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- 米国の筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- ヨーロッパの筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- アジア太平洋の筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- 中国の筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- 日本の筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- 韓国の筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- インドの筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- オーストラリアの筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- 中南米の筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）
- 中東・アフリカの筋緊張性ジストロフィー治療薬市場規模（2018年-2029年）

・種類別セグメント：ナトリウムチャネル遮断薬、三環系抗うつ薬、その他
- 世界の筋緊張性ジストロフィー治療薬のタイプ別販売量（2018年-2023年）
- 世界の筋緊張性ジストロフィー治療薬のタイプ別売上（2018年-2023年）
- 世界の筋緊張性ジストロフィー治療薬のタイプ別価格

・用途別セグメント：病院薬局、小売店薬局、その他
- 世界の筋緊張性ジストロフィー治療薬の用途別販売量（2018年-2023年）
- 世界の筋緊張性ジストロフィー治療薬の用途別売上（2018年-2023年）
- 世界の筋緊張性ジストロフィー治療薬の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Lupin、Teva、ANI Pharmaceuticals、Mylan、Novartis、Sun Pharma、Mallinckrodt

・産業チェーンと販売チャネルの分析
- 筋緊張性ジストロフィー治療薬産業チェーン分析
- 筋緊張性ジストロフィー治療薬の主要原材料
- 筋緊張性ジストロフィー治療薬の販売チャネル
- 筋緊張性ジストロフィー治療薬のディストリビューター
- 筋緊張性ジストロフィー治療薬の主要顧客

・筋緊張性ジストロフィー治療薬市場ダイナミクス
- 筋緊張性ジストロフィー治療薬の業界動向
- 筋緊張性ジストロフィー治療薬市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.
Highlights
The global Myotonic Dystrophy Drug market was valued at US$ 42 million in 2022 and is anticipated to reach US$ 67 million by 2029, witnessing a CAGR of 6.8% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Myotonic Dystrophy Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myotonic Dystrophy Drug.
The Myotonic Dystrophy Drug market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Myotonic Dystrophy Drug market comprehensively. Regional market sizes, concerning products by type, by distribution channel and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myotonic Dystrophy Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by distribution channel and by regions.
By Company
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt
Segment by Type
Sodium Channel Blocker
Tricyclic Antidepressant
Other
Segment by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Myotonic Dystrophy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Myotonic Dystrophy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by distribution channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Myotonic Dystrophy Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myotonic Dystrophy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Myotonic Dystrophy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Myotonic Dystrophy Drug industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myotonic Dystrophy Drug.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Myotonic Dystrophy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Myotonic Dystrophy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Myotonic Dystrophy Drug Market Overview
1.1 Product Overview and Scope of Myotonic Dystrophy Drug
1.2 Myotonic Dystrophy Drug Segment by Type
1.2.1 Global Myotonic Dystrophy Drug Market Value Comparison by Type (2023-2029)
1.2.2 Sodium Channel Blocker
1.2.3 Tricyclic Antidepressant
1.2.4 Other
1.3 Myotonic Dystrophy Drug Segment by Distribution Channel
1.3.1 Global Myotonic Dystrophy Drug Market Value by Distribution Channel: (2023-2029)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Global Myotonic Dystrophy Drug Market Size Estimates and Forecasts
1.4.1 Global Myotonic Dystrophy Drug Revenue 2018-2029
1.4.2 Global Myotonic Dystrophy Drug Sales 2018-2029
1.4.3 Global Myotonic Dystrophy Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Myotonic Dystrophy Drug Market Competition by Manufacturers
2.1 Global Myotonic Dystrophy Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Myotonic Dystrophy Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Myotonic Dystrophy Drug Average Price by Manufacturers (2018-2023)
2.4 Global Myotonic Dystrophy Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Myotonic Dystrophy Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Myotonic Dystrophy Drug, Product Type & Application
2.7 Myotonic Dystrophy Drug Market Competitive Situation and Trends
2.7.1 Myotonic Dystrophy Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Myotonic Dystrophy Drug Players Market Share by Revenue
2.7.3 Global Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Myotonic Dystrophy Drug Retrospective Market Scenario by Region
3.1 Global Myotonic Dystrophy Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Myotonic Dystrophy Drug Global Myotonic Dystrophy Drug Sales by Region: 2018-2029
3.2.1 Global Myotonic Dystrophy Drug Sales by Region: 2018-2023
3.2.2 Global Myotonic Dystrophy Drug Sales by Region: 2024-2029
3.3 Global Myotonic Dystrophy Drug Global Myotonic Dystrophy Drug Revenue by Region: 2018-2029
3.3.1 Global Myotonic Dystrophy Drug Revenue by Region: 2018-2023
3.3.2 Global Myotonic Dystrophy Drug Revenue by Region: 2024-2029
3.4 North America Myotonic Dystrophy Drug Market Facts & Figures by Country
3.4.1 North America Myotonic Dystrophy Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Myotonic Dystrophy Drug Sales by Country (2018-2029)
3.4.3 North America Myotonic Dystrophy Drug Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Myotonic Dystrophy Drug Market Facts & Figures by Country
3.5.1 Europe Myotonic Dystrophy Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Myotonic Dystrophy Drug Sales by Country (2018-2029)
3.5.3 Europe Myotonic Dystrophy Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Myotonic Dystrophy Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Myotonic Dystrophy Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Myotonic Dystrophy Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Myotonic Dystrophy Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Myotonic Dystrophy Drug Market Facts & Figures by Country
3.7.1 Latin America Myotonic Dystrophy Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Myotonic Dystrophy Drug Sales by Country (2018-2029)
3.7.3 Latin America Myotonic Dystrophy Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Myotonic Dystrophy Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Myotonic Dystrophy Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Myotonic Dystrophy Drug Sales by Type (2018-2029)
4.1.1 Global Myotonic Dystrophy Drug Sales by Type (2018-2023)
4.1.2 Global Myotonic Dystrophy Drug Sales by Type (2024-2029)
4.1.3 Global Myotonic Dystrophy Drug Sales Market Share by Type (2018-2029)
4.2 Global Myotonic Dystrophy Drug Revenue by Type (2018-2029)
4.2.1 Global Myotonic Dystrophy Drug Revenue by Type (2018-2023)
4.2.2 Global Myotonic Dystrophy Drug Revenue by Type (2024-2029)
4.2.3 Global Myotonic Dystrophy Drug Revenue Market Share by Type (2018-2029)
4.3 Global Myotonic Dystrophy Drug Price by Type (2018-2029)
5 Segment by Distribution Channel
5.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2018-2029)
5.1.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2018-2023)
5.1.2 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2024-2029)
5.1.3 Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2018-2029)
5.2 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2018-2029)
5.2.1 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2018-2023)
5.2.2 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2024-2029)
5.2.3 Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2018-2029)
5.3 Global Myotonic Dystrophy Drug Price by Distribution Channel (2018-2029)
6 Key Companies Profiled
6.1 Lupin
6.1.1 Lupin Corporation Information
6.1.2 Lupin Description and Business Overview
6.1.3 Lupin Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Lupin Myotonic Dystrophy Drug Product Portfolio
6.1.5 Lupin Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Teva Myotonic Dystrophy Drug Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 ANI Pharmaceuticals
6.3.1 ANI Pharmaceuticals Corporation Information
6.3.2 ANI Pharmaceuticals Description and Business Overview
6.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Product Portfolio
6.3.5 ANI Pharmaceuticals Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Mylan Myotonic Dystrophy Drug Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Novartis Myotonic Dystrophy Drug Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Sun Pharma
6.6.1 Sun Pharma Corporation Information
6.6.2 Sun Pharma Description and Business Overview
6.6.3 Sun Pharma Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sun Pharma Myotonic Dystrophy Drug Product Portfolio
6.6.5 Sun Pharma Recent Developments/Updates
6.7 Mallinckrodt
6.6.1 Mallinckrodt Corporation Information
6.6.2 Mallinckrodt Description and Business Overview
6.6.3 Mallinckrodt Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Mallinckrodt Myotonic Dystrophy Drug Product Portfolio
6.7.5 Mallinckrodt Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Myotonic Dystrophy Drug Industry Chain Analysis
7.2 Myotonic Dystrophy Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Myotonic Dystrophy Drug Production Mode & Process
7.4 Myotonic Dystrophy Drug Sales and Marketing
7.4.1 Myotonic Dystrophy Drug Sales Channels
7.4.2 Myotonic Dystrophy Drug Distributors
7.5 Myotonic Dystrophy Drug Customers
8 Myotonic Dystrophy Drug Market Dynamics
8.1 Myotonic Dystrophy Drug Industry Trends
8.2 Myotonic Dystrophy Drug Market Drivers
8.3 Myotonic Dystrophy Drug Market Challenges
8.4 Myotonic Dystrophy Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Myotonic Dystrophy Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Myotonic Dystrophy Drug Market Value Comparison by Distribution Channel (2023-2029) & (US$ Million)
Table 3. Global Myotonic Dystrophy Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Myotonic Dystrophy Drug Sales (K Unit) of Key Manufacturers (2018-2023)
Table 5. Global Myotonic Dystrophy Drug Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Myotonic Dystrophy Drug Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Myotonic Dystrophy Drug Average Price (USD$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Myotonic Dystrophy Drug, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Myotonic Dystrophy Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Myotonic Dystrophy Drug, Product Type & Application
Table 12. Global Key Manufacturers of Myotonic Dystrophy Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Myotonic Dystrophy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Myotonic Dystrophy Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Myotonic Dystrophy Drug Sales by Region (2018-2023) & (K Unit)
Table 18. Global Myotonic Dystrophy Drug Sales Market Share by Region (2018-2023)
Table 19. Global Myotonic Dystrophy Drug Sales by Region (2024-2029) & (K Unit)
Table 20. Global Myotonic Dystrophy Drug Sales Market Share by Region (2024-2029)
Table 21. Global Myotonic Dystrophy Drug Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2018-2023)
Table 23. Global Myotonic Dystrophy Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Myotonic Dystrophy Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Myotonic Dystrophy Drug Sales by Country (2018-2023) & (K Unit)
Table 27. North America Myotonic Dystrophy Drug Sales by Country (2024-2029) & (K Unit)
Table 28. North America Myotonic Dystrophy Drug Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Myotonic Dystrophy Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Myotonic Dystrophy Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Myotonic Dystrophy Drug Sales by Country (2018-2023) & (K Unit)
Table 32. Europe Myotonic Dystrophy Drug Sales by Country (2024-2029) & (K Unit)
Table 33. Europe Myotonic Dystrophy Drug Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Myotonic Dystrophy Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Myotonic Dystrophy Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Myotonic Dystrophy Drug Sales by Region (2018-2023) & (K Unit)
Table 37. Asia Pacific Myotonic Dystrophy Drug Sales by Region (2024-2029) & (K Unit)
Table 38. Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Myotonic Dystrophy Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Myotonic Dystrophy Drug Sales by Country (2018-2023) & (K Unit)
Table 42. Latin America Myotonic Dystrophy Drug Sales by Country (2024-2029) & (K Unit)
Table 43. Latin America Myotonic Dystrophy Drug Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Myotonic Dystrophy Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Myotonic Dystrophy Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Myotonic Dystrophy Drug Sales by Country (2018-2023) & (K Unit)
Table 47. Middle East & Africa Myotonic Dystrophy Drug Sales by Country (2024-2029) & (K Unit)
Table 48. Middle East & Africa Myotonic Dystrophy Drug Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Myotonic Dystrophy Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Myotonic Dystrophy Drug Sales (K Unit) by Type (2018-2023)
Table 51. Global Myotonic Dystrophy Drug Sales (K Unit) by Type (2024-2029)
Table 52. Global Myotonic Dystrophy Drug Sales Market Share by Type (2018-2023)
Table 53. Global Myotonic Dystrophy Drug Sales Market Share by Type (2024-2029)
Table 54. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2018-2023)
Table 57. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Type (2018-2023)
Table 59. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Type (2024-2029)
Table 60. Global Myotonic Dystrophy Drug Sales (K Unit) by Distribution Channel (2018-2023)
Table 61. Global Myotonic Dystrophy Drug Sales (K Unit) by Distribution Channel (2024-2029)
Table 62. Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2018-2023)
Table 63. Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2024-2029)
Table 64. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Distribution Channel (2018-2023)
Table 65. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Distribution Channel (2024-2029)
Table 66. Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2018-2023)
Table 67. Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2024-2029)
Table 68. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Distribution Channel (2018-2023)
Table 69. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Distribution Channel (2024-2029)
Table 70. Lupin Corporation Information
Table 71. Lupin Description and Business Overview
Table 72. Lupin Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2018-2023)
Table 73. Lupin Myotonic Dystrophy Drug Product
Table 74. Lupin Recent Developments/Updates
Table 75. Teva Corporation Information
Table 76. Teva Description and Business Overview
Table 77. Teva Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2018-2023)
Table 78. Teva Myotonic Dystrophy Drug Product
Table 79. Teva Recent Developments/Updates
Table 80. ANI Pharmaceuticals Corporation Information
Table 81. ANI Pharmaceuticals Description and Business Overview
Table 82. ANI Pharmaceuticals Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2018-2023)
Table 83. ANI Pharmaceuticals Myotonic Dystrophy Drug Product
Table 84. ANI Pharmaceuticals Recent Developments/Updates
Table 85. Mylan Corporation Information
Table 86. Mylan Description and Business Overview
Table 87. Mylan Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2018-2023)
Table 88. Mylan Myotonic Dystrophy Drug Product
Table 89. Mylan Recent Developments/Updates
Table 90. Novartis Corporation Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2018-2023)
Table 93. Novartis Myotonic Dystrophy Drug Product
Table 94. Novartis Recent Developments/Updates
Table 95. Sun Pharma Corporation Information
Table 96. Sun Pharma Description and Business Overview
Table 97. Sun Pharma Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2018-2023)
Table 98. Sun Pharma Myotonic Dystrophy Drug Product
Table 99. Sun Pharma Recent Developments/Updates
Table 100. Mallinckrodt Corporation Information
Table 101. Mallinckrodt Description and Business Overview
Table 102. Mallinckrodt Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2018-2023)
Table 103. Mallinckrodt Myotonic Dystrophy Drug Product
Table 104. Mallinckrodt Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Myotonic Dystrophy Drug Distributors List
Table 108. Myotonic Dystrophy Drug Customers List
Table 109. Myotonic Dystrophy Drug Market Trends
Table 110. Myotonic Dystrophy Drug Market Drivers
Table 111. Myotonic Dystrophy Drug Market Challenges
Table 112. Myotonic Dystrophy Drug Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Myotonic Dystrophy Drug
Figure 2. Global Myotonic Dystrophy Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Myotonic Dystrophy Drug Market Share by Type in 2022 & 2029
Figure 4. Sodium Channel Blocker Product Picture
Figure 5. Tricyclic Antidepressant Product Picture
Figure 6. Other Product Picture
Figure 7. Global Myotonic Dystrophy Drug Market Value Comparison by Distribution Channel (2023-2029) & (US$ Million)
Figure 8. Global Myotonic Dystrophy Drug Market Share by Distribution Channel in 2022 & 2029
Figure 9. Hospital Pharmacy
Figure 10. Retail Pharmacy
Figure 11. Other
Figure 12. Global Myotonic Dystrophy Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Myotonic Dystrophy Drug Market Size (2018-2029) & (US$ Million)
Figure 14. Global Myotonic Dystrophy Drug Sales (2018-2029) & (K Unit)
Figure 15. Global Myotonic Dystrophy Drug Average Price (USD$/Unit) & (2018-2029)
Figure 16. Myotonic Dystrophy Drug Report Years Considered
Figure 17. Myotonic Dystrophy Drug Sales Share by Manufacturers in 2022
Figure 18. Global Myotonic Dystrophy Drug Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Myotonic Dystrophy Drug Players: Market Share by Revenue in 2022
Figure 20. Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Myotonic Dystrophy Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Myotonic Dystrophy Drug Sales Market Share by Country (2018-2029)
Figure 23. North America Myotonic Dystrophy Drug Revenue Market Share by Country (2018-2029)
Figure 24. U.S. Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Myotonic Dystrophy Drug Sales Market Share by Country (2018-2029)
Figure 27. Europe Myotonic Dystrophy Drug Revenue Market Share by Country (2018-2029)
Figure 28. Germany Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Myotonic Dystrophy Drug Revenue Market Share by Region (2018-2029)
Figure 35. China Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Taiwan Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Myotonic Dystrophy Drug Sales Market Share by Country (2018-2029)
Figure 45. Latin America Myotonic Dystrophy Drug Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Colombia Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Myotonic Dystrophy Drug Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Myotonic Dystrophy Drug Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE Myotonic Dystrophy Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Myotonic Dystrophy Drug by Type (2018-2029)
Figure 56. Global Revenue Market Share of Myotonic Dystrophy Drug by Type (2018-2029)
Figure 57. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Myotonic Dystrophy Drug by Distribution Channel (2018-2029)
Figure 59. Global Revenue Market Share of Myotonic Dystrophy Drug by Distribution Channel (2018-2029)
Figure 60. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Distribution Channel (2018-2029)
Figure 61. Myotonic Dystrophy Drug Value Chain
Figure 62. Myotonic Dystrophy Drug Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 筋強直性ジストロフィー治療薬のグローバル市場展望 2023年-2029年：ナトリウムチャネル遮断薬、三環系抗うつ薬、その他
  • 不整脈治療の世界市場2023年：ナトリウムチャネル遮断薬、ベータ遮断薬、カリウムチャネル遮断薬、カルシウムチャネル遮断薬、その他
  • 世界のナルコレプシー治療薬市場2023-2030：治療別（脱力発作を伴うナルコレプシー、続発性ナルコレプシー）、製品別（酸化ナトリウム、三環系抗うつ薬）、地域別
  • 世界のナルコレプシー治療市場2023-2030：治療別（脱力発作を伴うナルコレプシー、続発性ナルコレプシー）、製品別（酸化ナトリウム、三環系抗うつ薬）、地域別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8824 )"筋緊張性ジストロフィー治療薬の世界市場2023年：ナトリウムチャネル遮断薬、三環系抗うつ薬、その他" (英文：Global Myotonic Dystrophy Drug Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。